303 related articles for article (PubMed ID: 24998822)
1. [Newly developed drug therapies for familial amyloid polyneuropathy: diflunisal and tafamidis].
Sekijima Y
Brain Nerve; 2014 Jul; 66(7):773-81. PubMed ID: 24998822
[TBL] [Abstract][Full Text] [Related]
2. Recent progress in the understanding and treatment of transthyretin amyloidosis.
Sekijima Y
J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
[TBL] [Abstract][Full Text] [Related]
3. TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies.
Adams D; Cauquil C; Labeyrie C; Beaudonnet G; Algalarrondo V; Théaudin M
Expert Opin Pharmacother; 2016; 17(6):791-802. PubMed ID: 26800456
[TBL] [Abstract][Full Text] [Related]
4. Tafamidis (Vyndaqel): a light for FAP patients.
Nencetti S; Rossello A; Orlandini E
ChemMedChem; 2013 Oct; 8(10):1617-9. PubMed ID: 24000164
[TBL] [Abstract][Full Text] [Related]
5. Tafamidis for transthyretin amyloidosis.
de Lartigue J
Drugs Today (Barc); 2012 May; 48(5):331-7. PubMed ID: 22645721
[TBL] [Abstract][Full Text] [Related]
6. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
7. [Clinical diversity, diagnosis and treatment of hereditary amyloid neuropathy].
Sekijima Y
Rinsho Shinkeigaku; 2014; 54(12):953-6. PubMed ID: 25672679
[TBL] [Abstract][Full Text] [Related]
8. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study.
Ando Y; Sekijima Y; Obayashi K; Yamashita T; Ueda M; Misumi Y; Morita H; Machii K; Ohta M; Takata A; Ikeda S
J Neurol Sci; 2016 Mar; 362():266-71. PubMed ID: 26944161
[TBL] [Abstract][Full Text] [Related]
9. FAP neuropathy and emerging treatments.
Adams D; Théaudin M; Cauquil C; Algalarrondo V; Slama M
Curr Neurol Neurosci Rep; 2014 Mar; 14(3):435. PubMed ID: 24482069
[TBL] [Abstract][Full Text] [Related]
10. [Familial amyloid polyneuropathies: therapeutic issues].
Adams D; Cauquil C; Théaudin M
Bull Acad Natl Med; 2012 Oct; 196(7):1333-45; discussion 1345-7. PubMed ID: 23815018
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of diflunisal on autonomic dysfunction of late-onset familial amyloid polyneuropathy (TTR Val30Met) in a Japanese endemic area.
Takahashi R; Ono K; Shibata S; Nakamura K; Komatsu J; Ikeda Y; Ikeda T; Samuraki M; Sakai K; Iwasa K; Kayano D; Yamada M
J Neurol Sci; 2014 Oct; 345(1-2):231-5. PubMed ID: 25060417
[TBL] [Abstract][Full Text] [Related]
12. [Familial amyloid polyneuropathy: clinicopathological aspects].
Koike H; Sobue G
Brain Nerve; 2014 Jul; 66(7):749-62. PubMed ID: 24998820
[TBL] [Abstract][Full Text] [Related]
13. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
[TBL] [Abstract][Full Text] [Related]
14. Current and future treatment of amyloid neuropathies.
Adams D; Cauquil C; Theaudin M; Rousseau A; Algalarrondo V; Slama MS
Expert Rev Neurother; 2014 Dec; 14(12):1437-51. PubMed ID: 25416603
[TBL] [Abstract][Full Text] [Related]
15. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial.
Keohane D; Schwartz J; Gundapaneni B; Stewart M; Amass L
Amyloid; 2017 Mar; 24(1):30-36. PubMed ID: 28393570
[TBL] [Abstract][Full Text] [Related]
16. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
Coelho T; Maia LF; Martins da Silva A; Waddington Cruz M; Planté-Bordeneuve V; Lozeron P; Suhr OB; Campistol JM; Conceição IM; Schmidt HH; Trigo P; Kelly JW; Labaudinière R; Chan J; Packman J; Wilson A; Grogan DR
Neurology; 2012 Aug; 79(8):785-92. PubMed ID: 22843282
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.
Sekijima Y; Ueda M; Koike H; Misawa S; Ishii T; Ando Y
Orphanet J Rare Dis; 2018 Jan; 13(1):6. PubMed ID: 29343286
[TBL] [Abstract][Full Text] [Related]
18. Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials.
Buxbaum JN
Amyloid; 2019 Jun; 26(2):55-65. PubMed ID: 30907141
[TBL] [Abstract][Full Text] [Related]
19. Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report.
Kon T; Misumi Y; Nishijima H; Honda M; Suzuki C; Baba M; Inomata Y; Obayashi K; Ando Y; Tomiyama M
Amyloid; 2015; 22(3):203-4. PubMed ID: 26123280
[No Abstract] [Full Text] [Related]
20. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
Merkies IS
Neurology; 2013 Apr; 80(15):1444-5. PubMed ID: 23569001
[No Abstract] [Full Text] [Related]
[Next] [New Search]
